Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1625288/000149315219010763/form8-k.htm
January 2022
July 2020
April 2020
October 2019
April 2019
March 2019
March 2019
March 2019
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1625288/000149315219010763/form8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Nexien Biopharma, Inc..
Nexien Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Nexien Biopharma, Inc. provided additional information to their SEC Filing as exhibits
Ticker: NXENEvents:
CIK: 1625288
Form Type: 8-K Corporate News
Accession Number: 0001493152-19-010763
Submitted to the SEC: Thu Jul 18 2019 9:00:11 AM EST
Accepted by the SEC: Thu Jul 18 2019
Period: Thursday, July 18, 2019
Industry: Pharmaceutical Preparations